[A23-108] Baricitinib (juvenile idiopathic arthritis) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-108
Commission:
Commission awarded on 13.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Children and adolescents 2 years of age and older with active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis)
- Patients who have had an inadequate response or intolerance to one or more prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs): added benefit not proven
- Patients who have had an inadequate response or intolerance to one or more prior biologic disease-modifying antirheumatic drugs (DMARDs): added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-108_en
| Project no. | Title | Status |
|---|---|---|
| A20-95 | Baricitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-14 | Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-114 | Baricitinib (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-109 | Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-113 | Baricitinib (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |